San Carlos, CA, United States of America

Josephine M Cardarelli

This inventor holds 43 USPTO granted patents and 23 published patent applications, plus 5 CIPO patents and 22 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Medarex Inc., E. R. Squibb Sons, Inc., Bristol-Myers Squibb Compnay. Active years: 2009-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Josephine M Cardarelli. Retrieved from https://idiyas.com/inventor/josephine-m-cardarelli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 23)

% Patents Active = 83.7

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 22 (Patent Applications = 21)

Average Co-Inventor Count = 4.9

ph-index = 12

Forward Citations = 1,856(Granted Patents)

Location History:

Redwood City, CA (US) (2019)
San Carlos, CA (US) (2009 - 2022)
Wellesley, MA (US) (2022)

Company Filing History:

E. R. Squibb Sons, Inc.

patents

9 out of 3,742

Bristol-Myers Squibb Compnay

patents

4. 8 out of 575

Ono Pharmaceutical Co., Ltd.

patents

5. 1 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2022

Loading Chart...

Areas of Expertise:

CXCR4

PD-1

Bispecific Antibodies

Interferon Alpha

Fucosyl-GM1

Cancer Treatment

Hematologic Malignancies

Waldenstrom's Macroglobulinemia

Human Monoclonal Antibodies

Combination Therapy

Immunotherapeutics

Nucleic Acids

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11312777 - Human monoclonal antibodies that bind CXCR4 and uses thereof (2022-04-26),

2. 11220548 - Treatment of-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody (2022-01-11),

3. 11104739 - Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody (2021-08-31),

4. 11072664 - Interferon receptor 1 antibodies and their uses (2021-07-27),

5. 10441655 - Monoclonal antibodies to programmed death 1 (PD-1) (2019-10-15),

6. 10428151 - Treatment of hematologic malignancies with an anti-CXCR4 antibody (2019-10-01),

7. 10385133 - Interferon receptor 1 antibodies and their uses (2019-08-20),

8. 10358490 - Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies (2019-07-23),

9. 10233248 - Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an anti-CXCR4 antibody (2019-03-19),

10. 10106615 - Nucleic acids encoding human monoclonal antibodies that bind CXCR4 (2018-10-23),

11. 9994633 - IP-10 antibodies and their uses (2018-06-12),

12. 9783606 - Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies (2017-10-10),

13. 9765141 - Methods for preparing interferon alpha antibodies (2017-09-19),

14. 9631025 - Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies (2017-04-25),

15. 9492540 - Methods for treating cancer using anti-PD-1 antibodies (2016-11-15),

Title: Josephine M. Cardarelli: A Pioneer in Monoclonal Antibody Research

Introduction

Josephine M. Cardarelli, based in San Carlos, California, is a notable inventor with an impressive portfolio of 43 patents. Her groundbreaking work primarily revolves around human monoclonal antibodies, which have significant implications in treating various cancers and inflammatory disorders.

Latest Patents

Among her latest patents, Cardarelli has been recognized for her remarkable innovation in the field of immunology with her patent on human monoclonal antibodies that bind CXCR4 and their uses. This patent outlines isolated monoclonal antibodies that exhibit high affinity toward the CXCR4 receptor. Additionally, the disclosure includes nucleic acid molecules encoding these antibodies, expression vectors, and host cells, along with methods for effective antibody expression. The patents also introduce immunoconjugates, bispecific molecules, and pharmaceutical compositions including her antibodies. Furthermore, methods for detecting CXCR4 and treating conditions such as various cancers, inflammatory disorders, and HIV infections using anti-CXCR4 antibodies are emphasized in her work.

Another significant patent addresses the treatment of Waldenstrom's macroglobulinemia, providing a method for treating patients afflicted with this condition by administering an antibody that specifically binds to the CXCR4 receptor on WM cells. This innovative approach showcases her dedication to advancing therapeutic strategies in oncology.

Career Highlights

Cardarelli has made significant contributions during her tenure at renowned companies like Medarex Inc. and E.R. Squibb & Sons, LLC. Her work in these organizations has not only enriched her professional journey but has also led to the development of critical therapeutic interventions.

Collaborations

Throughout her career, Cardarelli has collaborated with esteemed colleagues, including Mohan Srinivasan and Alison Witte. These partnerships have enabled the exchange of ideas and fostered innovation, further enhancing the landscape of monoclonal antibody research.

Conclusion

Josephine M. Cardarelli's contributions to the field of monoclonal antibodies underscore her status as a distinguished inventor. With her 43 patents, she is paving the way for novel therapeutic solutions that hold the potential to change lives and improve treatment outcomes for patients facing challenging health conditions. Her commitment to innovation and collaboration continues to inspire the scientific community.

Profile summary based on public USPTO records.